AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells

Leukemia

Volumn 21, Issue 5, 2007, Pages 877-885

  Griessinger, E ^a   Imbert, V ^a,b   Lagadec, P ^a,b   Gonthier, N ^a,b   Dubreuil, P ^a,c,d   Romanelli, A ^e   Dreano, M ^f   Peyron, J F ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e EMD SERONO INC   (United States)

^f Serono International SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIMETHOXY 2 PHENYLQUINOXALINE; AS 602868; BMS 345541; CASPASE; CD135 ANTIGEN; I KAPPA B KINASE; I KAPPA B KINASE 2; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; STAUROSPORINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LEUKEMOGENESIS; LYMPHOID CELL LINE; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN INDUCTION; SCHOOL CHILD;

EID: 34247609952     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404614     Document Type: Article

References (24)

1. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006; 441: 431-436.
2. Guzman M, Neering S, Upchurch D, Grimes B, Howard D, Rizzieri D et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
3. Frelin C, Imbert V, Griessinger M, Peyron A, Rochet N, Philip P et al. Targeting NF-κB activation via pharmacological inhibition of IKK2, induced apoptosis of human acute myeloid leukemia cells. Blood 2005; 105: 804-811.
4. Rayet B, Gélinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999; 18: 6938-6947.
5. Rosnet O, Buhring H, Marchetto S, Rappold I, Lavagna C, Sainty D et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 1996; 10: 238-248.
6. Stirewalt D, Radich J. The role of Flt3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3: 650-665.
7. Tse K, Mukherjee G, Small D. Constitutive activation of Flt3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 2000; 14: 1766-1776.
8. Gilliland D, Griffin J. Role of FLT3 in leukemia. Curr Opin Hematol 2002; 9: 274-281.
9. Levis M, Small D. FLT3 : ITDoes matter in leukemia. Leukemia 2003; 17: 1738-1752.
10. Levis M, Small D. FLT3 tyrosine kinase inhibitors. Int J Hematol 2005; 82: 100-107.
11. Tallman M, Gilliland D, Rowe J. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154-1163.
12. Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner BM, Mueller-Dieckmann C et al. Tyrosine phosphorylation of IκB-α activates NF-κB without proteolytic degradation of lκB-α. Cell 1996; 86: 787-798.
13. Deininger M, Buchdunger E, Drucker B. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105 2640-2653.
14. Sawyers C. Calculated resistance in cancer. Nat Med 2005; 11 824-825.
15. Kim H, Hawke N, Baldwin A. NF-κB and IKK as therapeuti targets in cancer. Cell Death Differentiation 2006; 13: 738-747.
16. Wang CY, Mayo MW, Baldwin Jr AS. TNF-α and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science 1996; 274: 784-787.
17. Yamamoto Y, Gaynor R. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135-142.
18. Frelin C, Imbert V, Griessinger M, Loubat A, Dreano M, Peyron J-F. AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic T cells. Oncogene 2003; 22: 8187-8194.
19. Takahashi S, Harigae H, Ishii K, Inomata M, Fujiwara T, Yokoyama H et al. over-expression of Flt3 induces NF-κB pathway and increases the expression of IL6. Leuk Res 2005; 29: 893-899.
20. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-225.
21. Birkenkamp K, Geugien M, Schepers H, Westra J, Lemmink H, Vellenga E. Constitutive NF-kappaB DNA-bonding activity in AML is frequently mediated by a Ras/P13-K/PKB-dependent pathway. Leukemia 2004; 18: 103-112.
22. Turco M, Romano M, Petrella A, Bisogni R, Tassone P, Venuta S. NF-κB/ Rel mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia 2004; 18: 11-17.
23. Minami Y, Yamamoto K, Kiyoi H, Ueda R, Saito H, Naoe T. Different antiapoptotic pathways between wild-type and mutated FLT3: Insights into therapeutic targets in leukemia. Blood 2003; 102: 2969-2975.
24. Cheng Q, Lee H, Li Y, Parks T, Cheng G. Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-κB inhibition. Oncogene 2000; 19: 4936-4940.